Literature DB >> 12781077

Advances in the management of malignant mesothelioma.

Mazen Y Khalil1, Marissa Mapa, Hyung Ju C Shin, Dong M Shin.   

Abstract

Malignant mesotheliomas are very aggressive tumors that originate from mesothelial cells, which form the serosal lining of the pleura, pericardial, and peritoneal cavities. Finding effective chemotherapeutic treatment for malignant mesothelioma is a challenge. There is no standard treatment because this tumor is relatively resistant to therapy. A resurgence of interest has been expressed in novel therapies and conventional treatments used in different ways. Several treatment modalities have been studied, including chemotherapy, radiotherapy, surgery, and immunotherapy. Chemotherapy can be administered systemically or directly into the pleura. This review presents the results of the most recent trials and highlights the most promising advances in the battle against this aggressive disease.

Entities:  

Mesh:

Year:  2003        PMID: 12781077     DOI: 10.1007/s11912-003-0076-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


  55 in total

1.  Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.

Authors:  K Fizazi; R Caliandro; P Soulié; A Fandi; C Daniel; A Bedin; H Doubre; J Viala; J Rodier; L Trandafir; T Le Chevalier; E Cvitkovic; J Armand; P Ruffié
Journal:  Eur J Cancer       Date:  2000-08       Impact factor: 9.162

2.  Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.

Authors:  L Strizzi; A Catalano; G Vianale; S Orecchia; A Casalini; G Tassi; R Puntoni; L Mutti; A Procopio
Journal:  J Pathol       Date:  2001-04       Impact factor: 7.996

3.  Phase II study of vinorelbine in patients with malignant pleural mesothelioma.

Authors:  J P Steele; J Shamash; M T Evans; N H Gower; M D Tischkowitz; R M Rudd
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

4.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

5.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Authors:  E Buchdunger; C L Cioffi; N Law; D Stover; S Ohno-Jones; B J Druker; N B Lydon
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

Review 6.  New molecular and epidemiological issues in mesothelioma: role of SV40.

Authors:  M Carbone; S Fisher; A Powers; H I Pass; P Rizzo
Journal:  J Cell Physiol       Date:  1999-08       Impact factor: 6.384

7.  Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.

Authors:  Charles Lu; Roman Perez-Soler; Bilal Piperdi; Garrett L Walsh; Stephen G Swisher; W Roy Smythe; Hyung J Shin; Jae Y Ro; Lei Feng; Mylene Truong; Adiseshu Yalamanchili; Gabriel Lopez-Berestein; Waun K Hong; Abdul R Khokhar; Dong M Shin
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

8.  Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma.

Authors:  A Procopio; L Strizzi; G Vianale; P Betta; R Puntoni; V Fontana; G Tassi; F Gareri; L Mutti
Journal:  Genes Chromosomes Cancer       Date:  2000-10       Impact factor: 5.006

9.  Cytogenetic analysis of malignant mesothelioma.

Authors:  A Hagemeijer; M A Versnel; E Van Drunen; M Moret; M J Bouts; T H van der Kwast; H C Hoogsteden
Journal:  Cancer Genet Cytogenet       Date:  1990-07-01

10.  A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.

Authors:  V Rusch; L Saltz; E Venkatraman; R Ginsberg; P McCormack; M Burt; M Markman; D Kelsen
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

View more
  1 in total

1.  Electrolyte and Fluid Transport in Mesothelial Cells.

Authors:  Hong-Long Ji; Hong-Guang Nie
Journal:  J Epithel Biol Pharmacol       Date:  2008
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.